Active peptide, peptide-containing composition and use thereof

Abstract

The present invention relates to the field of biotechnology, and in particular to an active peptide, a peptide-containing composition and uses thereof. The present invention provides a peptide represented by formula (I) or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, and a composition thereof for reducing water loss in the stratum corneum of the skin or preparing a skin moisturizing product. Experiments show that the peptide and the composition have good soothing effects, anti-oxidation effects and moisturizing effects.

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an active peptide, a peptide-containing composition and use thereof. Background Art

[0002] With the rapid improvement of people's living standards and material and cultural levels, people's demand for beauty is becoming more and more urgent. Cosmetics are favored by more people, and people begin to pursue natural cosmetics with good efficacy, few side effects and high safety. Green and natural have become the themes of cosmetic development. Peptides are a class of active substances with special physiological functions composed of a variety of amino acids. Bioactive peptides have the characteristics of easy absorption, easy processing, low sensitization, low osmotic pressure, etc. They have important application value in the fields of food, medicine, cosmetics, etc. Therefore, the use of peptide raw materials in cosmetics has increased dramatically.

[0003] Existing anti-inflammatory and soothing products designed for people with sensitive skin are not effective, and the products themselves may even be irritating to the skin. Therefore, it is of great practical significance to provide products with good soothing, antioxidant and moisturizing effects. Summary of the invention

[0004] In view of this, the present invention provides an active peptide, a peptide-containing composition and uses thereof, which have good soothing effect, good antioxidant effect and good moisturizing effect.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides the use of a peptide represented by formula (I) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a skin care product having soothing, firming or moisturizing effects.

[0007] Xaa1-Xaa2(I)

[0008] Among them, Xaa1 is acetylated β-alanine, and Xaa2 is a heterocyclic amino acid or a basic amino acid;

[0009] The soothing includes inhibiting the secretion of TNF-α inflammatory factor;

[0010] The firming includes inhibiting cellular ROS and / or increasing cellular SOD activity;

[0011] The moisturizing includes reducing the water loss of the stratum corneum of the skin and / or increasing the water content of the stratum corneum of the skin.

[0012] In some specific embodiments of the present invention, the Xaa2 in the above application is L-histidine.

[0013] In some specific embodiments of the present invention, the peptide in the above application is acetylcarnosine.

[0014] In some specific embodiments of the present invention, the peptide in the above application accounts for 0.1% to 1.0% of the net weight of the product.

[0015] The present invention also provides a composition comprising acetylcarnosine, Centella asiatica extract, Hamamelis virginiana extract, ectoine and acceptable adjuvants or auxiliary agents.

[0016] In some specific embodiments of the present invention, in the above composition, by weight, the acetylcarnosine is 1 to 10 parts, the Centella asiatica extract is 10 to 50 parts, the Hamamelis virginiana extract is 10 to 50 parts, and the tetrahydromethylpyrimidine carboxylic acid is 1 to 30 parts.

[0017] In some specific embodiments of the present invention, in the above-mentioned composition, the weight ratio of the acetylcarnosine, the Centella asiatica extract, the Hamamelis virginiana extract, and the tetrahydromethylpyrimidine carboxylic acid is 1:(1-50):(1-50):(0.1-30).

[0018] In some specific embodiments of the present invention, the composition consists of acetylcarnosine, Centella asiatica extract, witch hazel extract, tetrahydromethylpyrimidine carboxylic acid and water, wherein the concentration of acetylcarnosine is 0.1wt% to 1.0wt%, the concentration of Centella asiatica extract is 1.0wt% to 5.0wt%, the concentration of witch hazel extract is 1.0wt% to 5.0wt%, and the concentration of tetrahydromethylpyrimidine carboxylic acid is 0.1wt% to 3.0wt%.

[0019] The invention also provides a composition comprising acetylcarnosine, hyaluronic acid, Centella asiatica extract and acceptable auxiliary materials or adjuvants.

[0020] In some specific embodiments of the present invention, in the above composition, the acetylcarnosine is 10 to 100 parts, the hyaluronic acid is 1 to 10 parts, and the Centella asiatica extract is 100 to 500 parts by weight.

[0021] In some specific embodiments of the present invention, in the above composition, the weight ratio of the acetylcarnosine, the hyaluronic acid and the Centella asiatica extract is 1:(0.01-1):(1-50).

[0022] In some specific embodiments of the present invention, the composition consists of acetylcarnosine, hyaluronic acid, Centella asiatica extract and water, the concentration of acetylcarnosine is 0.1wt% to 1.0wt%, the concentration of hyaluronic acid is 0.01wt% to 0.1wt%, and the concentration of Centella asiatica extract is 1.0wt% to 5.0wt%.

[0023] The present invention also provides the use of the above composition in preparing skin care products;

[0024] The skin care products include skin care products with soothing, firming or moisturizing effects;

[0025] The skin care products include skin care products for anti-inflammation, skin care products for reducing water loss in the stratum corneum of the skin or skin care products for skin moisturizing.

[0026] The present invention also provides a skin care product, comprising the above composition and acceptable auxiliary materials or additives.

[0027] The invention also provides a method for preparing the skin care product, comprising the step of mixing acetyl carnosine with acceptable auxiliary materials or additives.

[0028] In some specific embodiments of the present invention, in the above-mentioned peptide, Xaa1 is acetylated β-alanine, and Xaa2 is a heterocyclic amino acid or a basic amino acid, especially L-histidine.

[0029] In some specific embodiments of the present invention, in the above-mentioned peptide, the Xaa1-Xaa2 does not contain at least one amino acid in the group consisting of amino acids Xaa1, Xaa2, or any combination thereof.

[0030] In some specific embodiments of the present invention, in the above-mentioned peptide, the amino acid modification in the Xaa1-Xaa2 is selected from the group consisting of β-alanine acetylation and histidine methylation.

[0031] In some specific embodiments of the present invention, the above-mentioned peptide, wherein in the Xaa1-Xaa2, the amino acid sequence is Acetyl-Ala-His-OH, a biologically active fragment thereof, a salt thereof, a combination thereof and / or a variant thereof.

[0032] In some specific embodiments of the present invention, the peptide, Xaa1-Xaa2 is acetyl carnosine, CAS No.: 56353-15-2, molecular formula C 11 H 16 N4O4, molar mass is 268.2691 g / mol.

[0033] The present invention also provides a composition comprising the above peptide and a cationic surfactant.

[0034] In some specific embodiments of the present invention, the composition has moisturizing, soothing and anti-oxidation effects for 20 minutes to 72 hours or longer.

[0035] In some specific embodiments of the present invention, the above-mentioned composition comprises additional active ingredients, which are selected from whitening agents, anti-redness agents, sunscreens and UV organic or inorganic filters, hydrating agents, moisturizing agents, wetting agents, scrubs, anti-wrinkle agents, anti-aging agents, slimming agents, anti-acne agents, anti-inflammatory agents, antioxidants, free radical scavengers, tanning agents, depilatory agents or shaving agents, hair growth slowing agents, tightening agents, peptides and vitamins.

[0036] The present invention also provides the use of the above-mentioned peptide and the above-mentioned composition in preventing and / or treating the intrinsic and extrinsic symptoms of skin aging: enhancing antioxidant effect, skin moisturizing, eliminating wrinkles, fine lines, skin cracks and improving skin roughness, enhancing skin tension and soothing skin, reducing skin sagging, skin spots and / or improving skin color brightness.

[0037] The present invention also provides the use of the peptide and the composition in improving the mechanical properties of the skin, the tension and / or stiffness and / or elasticity of the skin.

[0038] The present invention also provides a cosmetic method for treating wrinkles, comprising topically applying the above composition to the skin.

[0039] The active peptides, peptide-containing compositions and uses thereof of the present invention have the following effects:

[0040] 1. Compared with the negative control, the content of TNF-α inflammatory factor in the acetyl-carnosine sample group was significantly inhibited. The results showed that acetyl-carnosine has the ability to inhibit the secretion of TNF-α inflammatory factor;

[0041] 2. Compared with the negative control (light stimulation), the fluorescence intensity of ROS in the acetyl carnosine sample group decreased significantly, indicating that the product has the ability to inhibit the production of ROS in skin cells under light stimulation; in addition, compared with the negative control (light stimulation group), the enzyme activity of the acetyl carnosine sample group increased significantly, indicating that the product has the effect of promoting the activity of superoxide dismutase in skin cells under light stimulation;

[0042] 3. After a single use of the test sample "1% acetyl carnosine" on the inner forearm of the test subject for 2 hours, the results showed that after 2 hours of use of the test sample in the sample area, the moisture content of the skin stratum corneum increased significantly compared with the blank control area, indicating that the test sample has a 2h moisturizing effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0044] Figure 1Shows the content of TNF-α inflammatory factor in macrophages; “*” indicates significant difference compared with the negative control group (LPS group); “****”: p<0.0001;

[0045] Figure 2 It shows the inhibition rate of TNF-α inflammatory factor;

[0046] Figure 3 The fluorescence intensity of ROS in human keratinocytes is shown; “*” indicates a significant difference compared with the negative control group (UVA group); “**”: p<0.01; “***”: p<0.001;

[0047] Figure 4 Indicates superoxide dismutase activity; “*” indicates significant difference compared with the negative control group (UVA group); “***”: p<0.001; “****”: p<0.0001;

[0048] Figure 5 Schematic diagram of moisturizing effect test is shown;

[0049] Figure 6 The following is a comparative analysis of the changes in moisture content in the stratum corneum of the skin before and after the test between the sample area and the blank area; the significance in the figure indicates the significance of the difference between the sample area and the blank area at each time point and 0h before and after use, where "ns" means p>0.05, "*" means 0.01≤p<0.05; "**" means 0.01≤p<0.01, and "***" means p<0.001. The more the moisture content in the stratum corneum of the skin increases, the better the moisturizing effect of the product. DETAILED DESCRIPTION

[0050] The present invention discloses an active peptide, a peptide-containing composition and its use. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0051] Peptides can be developed or modified in a variety of ways. They have advantages such as better solubility, permeability, and receptor activity. Products with better soothing, antioxidant, and moisturizing effects can be obtained by adding peptides.

[0052] The purpose of the present invention is to protect the application of acetylcarnosine and its composition (pharmaceutical additive, anti-crystallization agent, hygroscopic agent, chemical stabilizer, food additive, surfactant, etc., which are widely used in medicine, chemical industry and tobacco).

[0053] The Centella asiatica extract involved in the specific embodiment is the Centella asiatica extract with batch number 20210811 produced by Guizhou Keyichuang Biotechnology Co., Ltd.

[0054] The witch hazel extract involved in the specific embodiment is the witch hazel extract with batch number 20221025 produced by Guizhou Keyichuang Biotechnology Co., Ltd.

[0055] Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all common commercial products and can be purchased from the market.

[0056] The present invention will be further described below in conjunction with embodiments:

[0057] Example 1: Acetylcarnosine Soothing Efficacy Test (In Vitro Determination of Inflammatory Factor Content)

[0058] (1) Experimental methods

[0059] The experiment was designed according to the standard of "T / SHRH 034-2021 Cosmetic Soothing Efficacy Test-In Vitro TNF-α Inflammatory Factor Content Determination Lipopolysaccharide-Induced Macrophage Inflammatory Cell Model Test Method", and the soothing effect of the sample was verified through sample groups, blank controls, negative controls and positive controls. Mouse macrophages were inoculated in 96-well plates for overnight culture. After LPS stimulation, different concentrations of sample solutions (ingredients: acetyl carnosine, concentrations of 500ppm, 50ppm, 5ppm, 0.5ppm, 0.1ppm), dexamethasone sodium phosphate (DSP), and purslane extract solution were added and incubated. The cell supernatant was collected, and the inflammatory factors were detected using a TNF-α enzyme-linked immunosorbent assay kit. The OD value of each sample well was detected at 450nm using an enzyme reader. The purslane extract was purchased from Guangzhou Hengtao Trading Co., Ltd.

[0060] (2) Correlation between experimental indicators and soothing effects

[0061] Inhibition rate (%) = (AB) / A*100%

[0062] A: OD value of the solution in the (1 μg / mL LPS) model group;

[0063] B: OD value of (LPS+sample solution; or LPS+Purslane solution);

[0064] The results of this experiment are characterized by the inhibition rate of the product on the inflammatory factor TNF-α. If the test sample has an inhibition rate compared with the model control, and the inhibition rate of the test product is significantly different from that of the model control, it means that the test sample has a soothing effect. The significant difference is statistically analyzed by SPSS software. When the significance factor P<0.05, it is considered to be significantly different.

[0065] (3) Experimental results

[0066] Table 1: Content and inhibition rate of TNF-α inflammatory factor secreted by macrophages under LPS stimulation culture conditions Figure 1 and Figure 2 Compared with the negative control, the TNF-α inflammatory factor content in the 500ppm, 50ppm, 5ppm, 0.5ppm, and 0.1ppm sample groups was significantly inhibited, with inhibition rates of 93.294%, 65.625%, 55.196%, 53.996%, and 46.555%.

[0067] Table 1: TNF-α inflammatory factor content and inhibition rate in macrophages

[0068]

[0069] (4) Experimental conclusion

[0070] Compared with the negative control, the TNF-α inflammatory factor content in the 500ppm, 50ppm, 5ppm, 0.5ppm, and 0.1ppm sample groups were significantly inhibited, with inhibition rates of 93.294%, 65.625%, 55.196%, 53.996%, and 46.555%, respectively. This indicates that acetyl carnosine has the ability to inhibit the secretion of TNF-α inflammatory factors. According to the experimental basis and the mechanism of skin irritation, this result can be used as one of the evidences to support the soothing effect claim of acetyl carnosine.

[0071] Example 2: Acetylcarnosine Antioxidant Efficacy Test (Determination of Cellular Active Oxygen Species Content)

[0072] (1) Experimental methods

[0073] The experiment was designed according to the standards such as "Evaluation Specifications for Cosmetic Efficacy Claims", "T / SHRH 032-2020 Cosmetic Firming and Anti-wrinkle Efficacy Test-In vitro Keratinocyte Reactive Oxygen Species (ROS) Inhibition Test Method" and "Study on Screening Antioxidants in Human Keratinocyte UV Damage Model". The antioxidant efficacy of the product was verified through sample groups, blank controls, negative controls and positive controls. After keratinocytes were inoculated in 12-well plates for overnight culture, they were pretreated with sample solutions of different concentrations (ingredients: acetyl carnosine, concentrations of 500ppm, 50ppm, 10ppm, 5ppm, and 0.5ppm) for 24 hours, and then irradiated with a certain dose of UVA. The blank group was cultured in the dark under the same conditions. ROS and superoxide dismutase (SOD) in the cells were detected 24 hours after irradiation. Finally, the production of ROS and changes in SOD activity were counted.

[0074] (2) Correlation between experimental indicators and antioxidant efficacy

[0075] ROS inhibition rate (%) = (AB) / A*100%

[0076] A: (cells after UVA stimulation) value of the model group solution;

[0077] B: value of (cells + sample solution after UVA stimulation);

[0078] The results of this experiment are characterized by the product's inhibition of ROS and changes in SOD activity. If ROS is inhibited and SOD activity is increased compared with the model control, and there is a significant difference between the test product and the model control, it means that the test sample has antioxidant capacity. The significant difference is statistically analyzed by SPSS software, and when the significance factor P<0.05, it is considered to be significantly different.

[0079] (3) Experimental results

[0080] ① Under light stimulation, the fluorescence intensity and inhibition rate of the test substances on ROS synthesized by human keratinocytes are shown in Table 2 and Figure 3 Compared with the negative control (light stimulation group), the fluorescence intensity of ROS in the 500ppm, 50ppm, 10ppm, 5ppm, and 0.5ppm sample groups decreased significantly, with inhibition rates of 68.144%, 51.924%, 21.049%, 22.085%, and 27.597%.

[0081] Table 2: Fluorescence intensity and inhibition rate of ROS in human keratinocytes

[0082]

[0083] ② The effects of the tested substances on the superoxide dismutase activity of human keratinocytes under light stimulation are shown in Table 3 and Figure 4 As shown, the superoxide dismutase activities of the 500ppm, 50ppm, 10ppm and 5ppm sample groups were 6.718U / mg, 4.6U / mg, 4.662U / mg and 3.231U / mg, respectively, and the enzyme activities increased significantly compared with the negative control (light stimulation group).

[0084] Table 3: Superoxide dismutase activity in the system

[0085]

[0086] (4) Experimental conclusion

[0087] Compared with the negative control (light stimulation), the fluorescence intensity of ROS in the 500ppm, 50ppm, 10ppm, 5ppm, and 0.5ppm sample groups all decreased significantly, with inhibition rates of 68.144%, 51.924%, 21.049%, 22.085%, and 27.597%, indicating that the product has the ability to inhibit the production of ROS in skin cells under light stimulation; in addition, the superoxide dismutase activity of the 500ppm, 50ppm, 10ppm, and 5ppm sample groups was 6.718U / mg, 4.6U / mg, 4.662U / mg, and 3.231U / mg, and compared with the negative control (light stimulation group), the enzyme activity increased significantly, indicating that the product has the effect of promoting the superoxide dismutase activity of skin cells under light stimulation. According to the experimental basis and the mechanism of skin aging, this result can be used as one of the evidences to support the antioxidant efficacy claim of acetyl carnosine raw materials.

[0088] Example 3: Acetylcarnosine Moisturizing Efficacy Test (Determination of Stratum Corneum Moisture Content)

[0089] (1) Experimental methods

[0090] A single-center open trial was conducted by using a test sample (1% (w / w) acetyl carnosine dissolved in water) on the front of the arm of at least 24 people once, using instrument testing, blank control, and before and after control methods to verify the 2-hour moisturizing effect of the product. Figure 5 It is a schematic diagram.

[0091] Test Equipment

[0092] ① Skin moisture tester, Cornemeter CM825, MPA580 (Courage & Khazaka, Germany)

[0093] ② Pipette, Microman E M100E (JC-R195, GILSON, France), Labserv junior pipette (JC-R193, Thermo Fisher Scientific (China) Co., Ltd.)

[0094] ③Analytical balance, FA305N (Shanghai Jinghai Instrument Co., Ltd., China)

[0095] Test environment

[0096] Test environment temperature: 21.0℃±1.0℃, humidity: 50±10%

[0097] Test parameter description

[0098] Water content of stratum corneum: The larger the parameter value, the higher the water content of the stratum corneum of the skin

[0099] The use period of the test sample: single use

[0100] Test site: Inner arm

[0101] (2) Correlation between experimental indicators and moisturizing efficacy

[0102] Descriptive statistics were performed on the measured values ​​of the sample area and the blank area, including the mean, standard deviation, minimum, median, maximum, and descriptive statistics were calculated using EXCEL. SPSS analysis software was used for statistical analysis of the data. The difference between the initial value of each test area and the measured value at other time points was calculated, and then this difference was used to statistically analyze the difference between the product area and the blank control area at different time points. If the test data was normally distributed, the t-test method was used for statistical analysis; if the test data was non-normally distributed, the rank sum test method was used for statistical analysis. The statistical methods all used two-tailed tests, and the test level α = 0.05.

[0103] According to the data analysis results, if the changes in the instrument test parameters in the sample area before and after using the product are significantly different (p<0.05), the test product is considered to have a moisturizing effect, otherwise it is considered that the test product has no moisturizing effect.

[0104] The graphs were drawn using Origin statistical software.

[0105] The parameter change rate is calculated by dividing the difference between the two mean values ​​by the mean value of the test before 0h.

[0106] Improvement rate % = sample side change rate (post-use test mean - pre-use test mean / pre-use test mean * 100%) - blank side change rate

[0107] Blank side change rate = Blank side T x Time test mean - blank side T0 time test mean / blank side T0 time test mean * 100%

[0108] Change value = post-test mean - pre-test mean

[0109] The results of this experiment are to characterize the product's ability to increase the moisture content of the skin's stratum corneum. If the test sample has a moisturizing effect compared with the model control, and there is a significant difference between the test product and the model control, it means that the test sample has a moisturizing effect. The significant difference is statistically analyzed using SPSS software, and when the significance factor P<0.05, it is considered to be significantly different.

[0110] (3) Experimental results

[0111] The test results of the stratum corneum moisture content in the test area and the control area are shown in Table 4. The original data are shown in Table 5, and the data analysis is shown in Tables 6 to 8. Figure 6 .

[0112] Table 4: Comparison results between sample area and blank area (number of people: 25)

[0113]

[0114] Table 5: Raw data

[0115]

[0116]

[0117] Statistical analysis results:

[0118] ① The analysis results of the balanced distribution of the sample area and the blank area 0h are shown in Table 6.

[0119] Table 6: Sample area and blank area 0h balance

[0120]

[0121] Descriptive statistics of the change:

[0122] ② The descriptive statistics of the change between the sample area and the blank area are shown in Table 7.

[0123] Table 7: Descriptive statistics of change (unit: au)

[0124]

[0125] Statistical analysis results:

[0126] ③ Comparison results between sample area and blank area. The comparison analysis results between sample area and blank area are shown in Table 8.

[0127] Table 8: Comparative analysis results of sample area and blank area

[0128]

[0129] ④ Comparative analysis of the difference in moisture content of the stratum corneum of the skin before and after the test between the sample area and the blank area, see Figure 6 .

[0130] (4) Experimental conclusion

[0131] The test sample "1% acetyl carnosine" was used once on the inner forearm of the subjects (25 Chinese men and women) for 2 hours. The test results of the sample area and the blank area showed that the moisture content of the stratum corneum of the skin increased significantly after the test sample was used for 2 hours in the sample area compared with the blank control area, which was significant (p<0.001), indicating that the test sample had a 2-hour moisturizing effect. The improvement rate of the stratum corneum moisture content was 12.06%. Example 4: Soothing effect test of a composition containing acetyl carnosine, Centella asiatica extract, witch hazel extract, and tetrahydromethylpyrimidine carboxylic acid

[0132] This example also studies the soothing effect of a composition comprising 1 to 10 parts of acetylcarnosine, 10 to 50 parts of Centella asiatica extract, 10 to 50 parts of witch hazel extract, 1 to 30 parts of tetrahydromethylpyrimidine carboxylic acid, and water as a solvent, proving that the composition comprising acetylcarnosine, Centella asiatica extract, witch hazel extract, and tetrahydromethylpyrimidine carboxylic acid has a synergistic effect on soothing.

[0133] (1) Experimental methods

[0134] The experiment was designed according to the standard of "T / SHRH 034-2021 Cosmetic Soothing Efficacy Test-In Vitro TNF-α Inflammatory Factor Content Determination Lipopolysaccharide-Induced Macrophage Inflammatory Cell Model Test Method". In this experiment, the IL-6 kit was used instead of the TNF-α kit. The soothing effect of the sample was verified by testing different sample raw materials, blank controls, negative controls and positive control groups. After mouse macrophages were inoculated in a 96-well plate and cultured overnight, after LPS stimulation, sample solutions containing different ingredients (ingredients: acetyl-carnosine, Centella asiatica extract and witch hazel extract and three active ingredient combinations, dexamethasone sodium phosphate (DSP)) were added respectively, and incubated separately. The cell supernatant was collected, and the inflammatory factors were detected using the IL-6 enzyme-linked immunosorbent assay kit, and the OD value of each sample well was detected at 450nm using an enzyme reader.

[0135] (2) Correlation between experimental indicators and soothing effects

[0136] Inhibition rate (%) = (AB) / A*100%

[0137] A: OD value of the solution in the (1 μg / mL LPS) model group;

[0138] B: OD value of (LPS+sample solution);

[0139] The results of this experiment are characterized by the inhibition rate of the product on the inflammatory factor IL-6. If the test sample has an inhibition rate compared with the model control, and the inhibition rate of the test product is significantly different from that of the model control, it means that the test sample has a soothing effect. The significant difference is statistically analyzed by SPSS software. When the significance factor P<0.05, it is considered to be significantly different.

[0140] (3) Experimental results

[0141] Under LPS stimulation culture conditions, the content and inhibition rate of IL-6 inflammatory factor secreted by macrophages by the test substances are shown in Table 9. Compared with the LPS group, the content of IL-6 inflammatory factor in the sample groups of acetyl carnosine, Centella asiatica extract, and Hamamelis virginiana extract were significantly inhibited, with inhibition rates of 66.46%, 46.2%, and 35.25%, respectively. Among them, the sample group containing the three active ingredients at the same time had the highest inhibition rate, ranging from 88.11% to 94.44%. Compared with a single component, the combination is more effective in anti-inflammatory.

[0142] Table 9: IL-6 test results

[0143]

[0144] Example 5: Moisturizing effect test of a composition containing acetylcarnosine, hyaluronic acid and Centella asiatica extract

[0145] This example also studies the moisturizing effect of a composition comprising 10 to 100 parts of acetyl carnosine, 1 to 10 parts of hyaluronic acid, 100 to 500 parts of Centella asiatica extract, and water as a solvent, demonstrating that the composition comprising acetyl carnosine, hyaluronic acid, and Centella asiatica extract has a synergistic effect on moisturizing.

[0146] 50 volunteers aged between 30 and 60 years old, including 15 males and 35 females, were randomly divided into 5 groups, with 10 people in each group. A 5×5cm effective area was selected on the skin for the experiment. The blank group was a skin care product without the three ingredients. The active ingredient of the positive group was 1% Ecdoin, and the solvent was water. The other groups contained different proportions of active ingredients, which were applied to the skin respectively. The German CK skin moisture tester Corneometer CM825 was used to measure the skin moisture content of each subject at different times under the same test environment (21.0℃±1.0℃, humidity: 50±10%). The skin moisture content before application was measured as T0-initial value, and the skin moisture content 2h after application was measured as T2-2 h. The larger the value, the higher the skin moisture content, indicating that the moisturizing effect is better.

[0147] Table 10: Moisture test

[0148] Grouping T0-initial value (%) T2-2 h(%) Blank Group 31.6 32.3 Positive group 32.1 50.1 0.1% Acetylcarnosine Group 30.9 50.03 1% Acetyl Carnosine Group 31.3 53.21 0.01% hyaluronic acid group 31.5 52.60 0.1% hyaluronic acid group 31.2 53.02 1% Centella Asiatica Extract Group 31.1 50.38 5.0% Centella asiatica extract group 31.5 53.17 0.01% Hyaluronic Acid + 1% Centella Asiatica Extract Set 31.3 53.25 0.01% hyaluronic acid + 5.0% Centella asiatica extract combination 30.7 53.86 0.1% Hyaluronic Acid + 1% Centella Asiatica Extract Set 31.2 54.05 0.1% Acetyl Carnosine + 0.01% Hyaluronic Acid + 1% Centella Asiatica Extract Set 31.7 59.93 0.1% Acetyl Carnosine + 0.1% Hyaluronic Acid + 1.0% Centella Asiatica Extract Set 31.2 60.80 1.0% Acetyl Carnosine + 0.01% Hyaluronic Acid + 5.0% Centella Asiatica Extract Set 30.7 61.66 1% Acetyl Carnosine + 0.1% Hyaluronic Acid + 1% Centella Asiatica Extract Set 30.8 63.26

[0149] It can be seen from the experimental data in Table 10 that, compared with the blank group, the skin moisture content was significantly increased after 2 hours of use, wherein the composition of acetyl carnosine, hyaluronic acid and Centella asiatica extract added simultaneously can effectively improve the skin moisturizing effect.

[0150] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of a peptide represented by formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the preparation of a skin care product having soothing, firming or moisturizing effects, Xaa1-Xaa2(I) in, Xaa1 is acetylated β-alanine, and Xaa2 is a heterocyclic amino acid or a basic amino acid; The soothing includes inhibiting the secretion of TNF-α inflammatory factor; The firming includes inhibiting cellular ROS and / or increasing cellular SOD activity; The moisturizing includes reducing the water loss of the stratum corneum of the skin and / or increasing the water content of the stratum corneum of the skin.

2. The use according to claim 1, characterized in that The Xaa2 is L-histidine.

3. The use according to claim 1, characterized in that The peptide is acetylcarnosine.

4. The use according to claim 1, characterized in that The peptide accounts for 0.1 wt% to 1.0 wt% of the net weight of the product.

5. A composition, characterized in that It includes acetyl carnosine, Centella asiatica extract, witch hazel extract, tetrahydromethylpyrimidine carboxylic acid and acceptable excipients or adjuvants.

6. The composition according to claim 5, characterized in that In parts by weight, the acetylcarnosine is 1 to 10 parts, the Centella asiatica extract is 10 to 50 parts, the witch hazel extract is 10 to 50 parts, and the ectoine is 1 to 30 parts.

7. A composition, characterized in that It comprises acetyl carnosine, hyaluronic acid, Centella asiatica extract and acceptable excipients or adjuvants.

8. The composition according to claim 7, characterized in that In parts by weight, the acetyl carnosine is 10 to 100 parts, the hyaluronic acid is 1 to 10 parts, and the Centella asiatica extract is 100 to 500 parts.

9. Use of the composition according to any one of claims 5 to 8 in the preparation of skin care products; The skin care products include skin care products for anti-inflammation, skin care products for reducing water loss in the stratum corneum of the skin or skin care products for skin moisturizing.

10. A skin care product, characterized in that The composition comprises the composition according to any one of claims 5 to 8, and acceptable adjuvants or auxiliary agents.

11. A method for preparing a skin care product, characterized in that: The method comprises the steps of mixing acetyl carnosine with acceptable auxiliary materials or additives.

Images